Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read the original:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and... - Azizsalon News

: New York, United States, 31-July-2020, (Via WiredRelease), (Reports and Data) The global nanomedicine market is expected to reach USD 343.8 billion by 2026, according to a new report by Reports and Data. Increased global incidence of cancer coupled with growing prevalence of cardiovascular diseases is likely to be the key factors governing market growth. Based on the WHO statistics, in 2018 around 18.07million new cases were registered for cancer in 2018. Additionally, cancer accounted for around 9.5 million deaths in 2018. The incidence of cancer was significantly high and lied around 48.4 percent in Asia Pacific.

Nanomedicine is being increasingly adopted for the treatment of various diseases including cancer and cardiovascular disease. Apart from improved efficacy and safety, factors such as bio-availability and ability to deliver diagnostic and therapeutic agents to targeted sites are expected to stimulate market growth.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.reportsanddata.com/sample-enquiry-form/1048

The COVID-19 impact: Covid-19s spread has affected manufacturing and construction activities worldwide. Logistic limitations and reconsiderations of the raw material requirements are becoming a problem for producers. The producers have relied on derived demand as an intermediate commodity to rationalize production. The pandemics economic impact on companies and financial markets is also not favorable. Stock market volatility and decreasing global growth are anticipated, which will affect the market. The market has experienced a downturn over the weeks, which may continue over the next few months. The Asia Pacific is the most affected region by this pandemic, with China at the center of the outbreak. Most initiatives in multiple countries have changed to a temporary halt. Development, as well as supply, is put on hold, creating losses for suppliers, dealers and customers alike.

Key participants include

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation and Johnson & Johnson.

Get Discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

For the purpose of this report, Reports and Data have segmented into the global Nanomedicine market on the basis of type, propellants, application, and region:

For the purpose of this report, Reports and Data have segmented global Nanomedicine Market on the basis of products, drug delivery system, application and region:

Product Outlook (Revenue, USD Billion,2018-2026)TherapeuticsRegenerative MedicineIn-vitro diagnosticsIn-vivo diagnosticVaccines

Drug Delivery System Outlook (Revenue, USD Billion, 2018-2026)NanobotsNanoghostsNanoclustersNanobubblesExosomesInjectable Nanoparticle GeneratorDendrimersLiposomesCarbon nanotubeGrapheneOthersApplicationOutlook (Revenue, USD Million, 2015-2026)OncologyInfectious diseasesCardiologyOrthopedicsOthers

Regional Outlook (Revenue, USD Million; 2017-2027)

North America

U.S

Europe

U.K

France

Asia Pacific

China

India

Japan

MEA

Latin America

Brazil

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/nanomedicine-market

Key aspects of the Nanomedicine Market Report:

The report comprises of Nanomedicine market overview, market share, demand and supply ratio, supply chain analysis, and import/export details.

The report explores different strategies and procedures undertaken by key market players that assist in making profitable decisions.

The report covers all the crucial information about the products and services of major competitors.

About Us: Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development.

Contact Us: John WatsonHead of Business DevelopmentReports and Data | Web: http://www.reportsanddata.comDirect Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

This content has been published by MARKETYSERS GLOBAL CONSULTING LLP company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Read more:
Nanomedicine Market To Reach USD 343.8 Billion By 2026 | CAGR of 12.6% (1) - PharmiWeb.com

UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society (SFNano), and the French national Competency Cluster in Nanoscience CNano which was held in Dijon in early December.

Nanoparticles (NPs) have demonstrated great potential in diagnostic medicine particularly as contrast agents using MRI scanners. Iron oxide, gold, and gadolinium NPs have been used in preclinical and clinical studies as contrast enhancing agents.

The participants at the SFNano CNano 2019 joint meeting work in the scientific areas of nanomedicine, nanotechnology and nanoscience. MR Solutions presented the technology in a talk to the scientific community and displayed the PET/MRI system at the accompanying exhibition.

MR Solutions 7T PET/MR preclinical imaging system uses dry magnet, or liquid-helium free technology facilitating a compact system for multi-modality imaging. Researchers are able to combine high resolution MRI data with the high sensitivity of PET data for anatomical and quantitative studies.

Fabrice Chaumard, MR Solutions sales and marketing director commented: We were delighted that there was so much interest from the scientific community in our preclinical PET/MRI systems for nanoparticle imaging. This system provides much better imaging data and at a fraction of the cost of two separate systems.

The PET capability is provided by solid state detectors which are incorporated in the bore of the MRI scanner. The scanner combines the exquisite structural and functional characterisation of tissue provided by MRI with the extreme sensitivity of PET imaging for metabolism and tracking of uniquely labelled cell types or cell receptors. This is particularly useful in oncology, cardiology, and neurology research.

MR Solutions is the worlds leading independent developer and manufacturer of preclinical multi-modality MRI technology and remains the only company to deliver a commercial cryogen-free 3T to 9.4T range of compact MRI scanners. In recognition of the companys innovation and business acumen the company has received three Queens Awards for Enterprise for innovation in 2016 and 2019 and for international trade in 2017.

MR Solutions has over 30 years experience and in excess of 2000 installations across the world. This includes sales of their MRI spectrometers. Its scanners are renowned for their excellence in terms of superior soft tissue contrast and molecular imaging ability.

http://www.mrsolutions.com .

< Ends

Visit link:
MR Solutions participates in the first nanomedicine joint annual meeting in Dijon - BioSpace

The unfolding Sars-2-CoV outbreak is laying bare the worlds need for effective antivirals. According to University of Lille chemist Sabine Szunerits, we should invest in this now, knowing that viruses will be an issue in the 21st century. With this in mind she and collaborators at the Pasteur Institute in Lille, France have, over the past few years, been developing a new approach to tackling viruses including coronaviruses that takes advantage of the unique properties of nanoparticles.

There are only a handful of approved antiviral treatments and these are only effective against a few specific viruses. This means that when new viral diseases like Covid-19 emerge doctors are left trying to repurpose existing antivirals in the hope that they will have an effect on the new disease.

Viruses are not technically alive, they are packages of RNA or DNA that can only replicate by hijacking its hosts genetic machinery. Antivirals do not destroy these packages, they are small molecules designed to block viral replication, thereby reducing symptoms and infectivity while the immune system deals with them. Unfortunately, because viruses rely on the hosts DNA replication machinery finding drugs that only target and bind specific virus proteins and not those of the host cell is a challenge. This lack of specificity means large doses of antivirals are often needed to achieve the desired effect, which in turn increases toxicity.

The field of nanomedicine, however, has been exploring how nanoparticles can overcome some of these problems. The promise of nanoparticle antivirals comes from their multivalency the number of interactions occurring as molecules bind together. The nanoparticle of choice for Szunerits are carbon quantum dots (CQDs) which are spherical, have a high surface-to-volume ratio and are smaller in size than viruses creating conditions where multivalent interactions can play a role. The surface of the CQDs can also be coated with molecules that bind the proteins viruses use to enter cells. The spherical shape and smaller size of the CQD mean these molecules can form extremely tight multivalent bonds with proteins all over the viruss surface, blocking it from attaching to and infecting a host cell. Szunerits and team started this work in 2018, testing the ability of CQDs with boronic acid groups to reduce the infectivity of a mild strain of human coronaviruses in cell lines.They achieved significant reductions in viral entry relative to controls and are now working on CQDs coated with Middle East Respiratory Syndrome (MERS) specific peptides, showing that CQDs should be able to be adapted to specific viral threats.

Cameron Alexander at the University of Nottingham, who works with nanoparticle-based RNA vaccines sees the potential adaptability of this type approach. Once youve got a nanoparticle with the right spacing and chemical functionalities to match one virus, its not inconceivable to think how you could plug and play different groups on that surface to find another virus.

Igor Medintz, a senior scientist with the US Naval Research Laboratory in Washington DC, agrees that the plug and play nature of this approach is promising because, as long as a molecule is biocompatible, there are few limitations to the options available. Theres a huge library of non-natural amino acids that can be accessed as well you can synthesise peptides with just about any chemical or functional group possible and those could give them very high binding affinity beyond the naturally occurring ones, he says.

Another drawback of current antivirals is that they are often insoluble making administering them more difficult. Often drugs on the market are rather hydrophobic and the pharma industry always likes delivering drugs orally, says Szunerits. Nanoparticles like CQDs are hydrophilic, however, allowing them to circulate better. Due to their size, they are also easier to deliver as a fine spray, which for infections that affect the lungs, such as coronaviruses, would be more effective.

Right now, Szunerits and the team are experimenting with liposome packages to deliver CQDs, as well as assessing the big question of how the body will handle them once theyve serve their function. Early studies by her group have shown that CQDs injected into mice are passed in urine, which along with in vitro toxicity studies provide hopeful signs that the body can tolerate them.

As with any new treatment moving from the lab to clinical trials and then scaling-up production is a long road. According to Alexander, making these types of particles is easy enough but ensuring uniformity in large batches required for a therapeutic becomes problematic. When youre making some of these systems, you need to check that the size is correct, the functionality is correct and the more functionality you put in it, the more complicated they are to characterise, he says. The more complicated to characterise, the harder it is to get regulatory approval, and the harder it is to manufacture.

Visit link:
Nanoparticle antivirals offer new way to fight coronaviruses but therapy is still in its infancy - Chemistry World

Back to Browse Journals International Journal of Nanomedicine Volume 12

Di Wu, Mengjie Si, Hui-Yi Xue, Ho-Lun Wong

Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA

Abstract: Breast cancer is the most common malignant disease in women worldwide, but the current drug therapy is far from optimal as indicated by the high death rate of breast cancer patients. Nanomedicine is a promising alternative for breast cancer treatment. Nanomedicine products such as Doxil and Abraxane have already been extensively used for breast cancer adjuvant therapy with favorable clinical outcomes. However, these products were originally designed for generic anticancer purpose and not specifically for breast cancer treatment. With better understanding of the molecular biology of breast cancer, a number of novel promising nanotherapeutic strategies and devices have been developed in recent years. In this review, we will first give an overview of the current breast cancer treatment and the updated status of nanomedicine use in clinical setting, then discuss the latest important trends in designing breast cancer nanomedicine, including passive and active cancer cell targeting, breast cancer stem cell targeting, tumor microenvironment-based nanotherapy and combination nanotherapy of drug-resistant breast cancer. Researchers may get insight from these strategies to design and develop nanomedicine that is more tailored for breast cancer to achieve further improvements in cancer specificity, antitumorigenic effect, antimetastasis effect and drug resistance reversal effect.Keywords: nanomedicine, breast cancer, targeted delivery, drug therapy, drug resistance, tumor microenvironment

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Nanomedicine applications in the treatment of breast cancer: current state of the art - Dove Medical Press

Michelle Bradbury MD, PhD, who is a Professor of Radiology, Director of Intraoperative Imaging, and Co-Director of an National Cancer Institute awarded Nanomedicine Center (MSK-Cornell Center for Translation of Cancer Nanomedicines), has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care.

Dr. Michelle S. Bradbury is a highly experienced physician who has been in practice for over two decades. Her career in medicine started in 1997, when she graduated from the George Washington University School of Medicine and Health Sciences in Washington, D.C. An internship, residency and then fellowship followed, all completed at Wake Forest University in Winston-Salem, North Carolina. Dr. Bradbury also holds a Doctor of Philosophy Degree from the Massachusetts Institute of Technology.

Dr. Bradbury is certified by the American Board of Radiology in both Diagnostic Radiology and Neuroradiology. She is particularly renowned, however, as a leading expert in nanomedicine and in neuroradiology, using CT and MRI imaging of the brain, neck and spine to diagnose conditions of the nervous system. Alongside her work in this field she has been at the forefront of nanomedicine research and clinical trials.

Dr. Bradbury keeps up to date with the latest advances in her field through her active membership of professional organizations including the American College of Radiology, the World Molecular Imaging Congress, and the American Society of Nanomedicine. Her expertise and dedication makes Dr. Michelle S. Bradbury a very deserving winner of a 2017 Top Doctor Award.

About Top Doctor Awards

Top Doctor Awards specializes in recognizing and commemorating the achievements of todays most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors

See the original post here:
Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor ... - PR NewsChannel (press...

Global Nanomedicine Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Nanomedicine Market.

Companies Mentioned are GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A.

Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the global market size of Nanomedicine based on end-use industry and region, in terms of value. With the data triangulation procedure and validation of data through primary interviews, the exact values of the overall parent market, and individual market sizes were determined and confirmed in this study.

Sample/Inquire at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017/inquiry

This report segments the global Nanomedicine market on the basis of types Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery. On the basis of application Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology.

Essential points covered in Global Nanomedicine Market 2017 Research are:-

This independent 116 page report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Nanomedicine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.

The global Nanomedicine market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Browse Full Report at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Storage Area Network Switch in these regions, from 2012 to 2022 (forecast), covering

by Regions

The report provides a basic overview of the Nanomedicine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Nanomedicine industry development trends and marketing channels are analyzed.

The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Nanomedicine on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Nanomedicine Market and assist manufacturers and investment organization to better grasp the development course of Nanomedicine Market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

There are 15 Chapters to deeply display the global Nanomedicine market.

Chapter 1, to describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Nanomedicine, with sales, revenue, and price of Nanomedicine, in 2016and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Nanomedicine, for each region, from 2012to 2017;

Chapter 5, 6, 7,8and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Nanomedicine market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;

Chapter 13, 14 and 15, to describe Nanomedicine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Original post:
Nanomedicine Market Growth Opportunities for Distributers 2017 - Equity Insider (press release)

Killer T cells surround a cancer cell. Credit: NIH

Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor initiating cells (BTICs).

"BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy," explained the study's first author, Dr. Dou Yu, research assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine.

The findings were published in the journal Proceedings of the National Academy of Sciences.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA)short sequences of RNA molecules that reduce the expression of specific cancer promoting proteinsdirectly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

"This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind," said Yu, who collaborated on the research with principal investigator Dr. Maciej Lesniak, Michael J. Marchese Professor of Neurosurgery and chair of neurological surgery.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patient's tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissuesbut not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

"This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling," Yu said. "Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits."

The strategy could also apply to other medical conditions related to the central nervous systemnot just brain tumors.

"Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform," Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

"Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer," Lesniak summed up.

Explore further: Cold virus, stem cells tested to destroy deadly brain cancer

More information: Dou Yu et al, Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1701911114

The rest is here:
Nanomedicine opens door to precision medicine for brain tumors - Phys.Org

Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16th to 18th of July.

The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.

The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.

The rest is here:
Precision NanoSystems to Host Nanomedicines Symposium - Technology Networks

Nanomedicine RA with Dr. Bottini
Dr. Massimo Bottini, a researcher and bio-engineer who splits his time between the University of Rome and the Sanford Burnham Medical Research Institute in S...

By: Arthritis National Research Foundation

Link:
Nanomedicine & RA with Dr. Bottini - Video

The worldwide Nanomedicine Market report is an in-depth research on the current situation of the Nanomedicine industry. The research study of Global Nanomedicine Market 2017 offers a strategic assessment of Nanomedicine market. The industry report focuses on the growth opportunities, which will help the Nanomedicine industry to expand operations in the existing markets globally.

Firstly, Nanomedicine Market report introduces a basic overview of the Nanomedicine industry, which includes Nanomedicine definitions, applications, classifications and Nanomedicine industry chain structure. Worldwide Nanomedicine market analysis is provided for the international market including Nanomedicine industry competitive analysis, Nanomedicine market development history and major sectors development status on Nanomedicine industry scenario.

Get Sample Report Here: https://market.biz/report/global-nanomedicine-market-2017/61375/#inquiry

Global Nanomedicine Market 2017: Competitive Landscape and Key Vendors

1 GE Healthcare 2 Johnson & Johnson 3 Mallinckrodt plc 4 Merck & Co. Inc. 5 Nanosphere Inc. 6 Pfizer Inc. 7 Sigma-Tau Pharmaceuticals Inc. 8 Smith & Nephew PLC 9 Stryker Corp 10 Teva Pharmaceutical Industries Ltd. 11 UCB (Union chimique belge)

Nanomedicine Market 2017: Type Segment Analysis

Regenerative Medicine In-vitro & In-vivo Diagnostics Vaccines Drug Delivery

Nanomedicine Market 2017: Applications Segment Analysis

Clinical Cardiology Urology Genetics Orthopedics Ophthalmology

The Nanomedicine market covers the geological regions including US, EU, China, and Japan. Other regions can also be added efficiently as per customers need. The report also displays the market size for each category during the forecasting period from 2017 to 2022.

Further, the report guides the client according to the various aspects of Nanomedicine industry like supply chain analysis, Nanomedicine industry rules, and policies, along with product cost, product images, the cost structure, import/export information and utilisation figures. The detailed competitive plan of Nanomedicine industry report will help the clients to systematically specify better business strategies for a desired business payoff.

To Purchase Complete Report Click Here: https://market.biz/report/global-nanomedicine-market-2017/61375/

At the end, report Global Nanomedicine Market 2017 focuses the feasibility of new investment projects is assessed, and overall research conclusions are offered on Nanomedicine market scenario.

More:
Global Nanomedicine Market 2017 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc. - Ask Reporter 24

Insights on the Global Healthcare Nanotechnology (Nanomedicine) Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Healthcare Nanotechnology (Nanomedicine) market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Healthcare Nanotechnology (Nanomedicine) market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Critical doubts related to the Healthcare Nanotechnology (Nanomedicine) market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Segmentation of the Healthcare Nanotechnology (Nanomedicine) market

The report bifurcates the Healthcare Nanotechnology (Nanomedicine) market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Healthcare Nanotechnology (Nanomedicine) market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Healthcare Nanotechnology (Nanomedicine) market.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Important insights present in the report:

See more here:
Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 - Jewish Life News

Cellular Surgeons: The New Era of Nanomedicine - Full Program
Pills the size of molecules to seek and destroy tumors. Miniscule robots performing surgery inside patients with a precision never before achieved. Nanobots, a billionth of a meter across,...

By: World Science Festival

Excerpt from:
Cellular Surgeons: The New Era of Nanomedicine - Full Program - Video

DUBLIN--(BUSINESS WIRE)--The "Innovations in Wellness, Biotech, and Digital Health Platforms" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) analyzes recent advances in 3D food printing for health & wellness, and latest developments across drug discovery, development, and delivery platforms. The TOE also provides insights across innovative precision therapy technologies and digital health platforms.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery, and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/acrspx

Go here to see the original:
Innovations in Wellness, Biotech, and Digital Health Platforms, 2019 Research Report - ResearchAndMarkets.com - Business Wire

With the outbreak of the Wuhan coronavirus in China and the increasing death toll, there is little doubt that global financial markets are going to be impacted negatively. As Trump considers banning all flights to China, airline and travel companies like United Airlines (NASDAQ:UAL), Expedia (NASDAQ:EXPE), American Airlines (NASDAQ:AAL) and many more have seen their stock prices crash. There is a strong negative sentiment on the Chinese economy as a whole as the virus has shaken up many of the erstwhile strong sectors.

Overview of the virus

For those readers who are not aware, the Wuhan coronavirus first emerged in the central Chinese city of the same name through the meat and seafood markets and has spread across the country with over a thousand cases and more than a hundred deaths confirmed. It belongs to the same family of viruses as SARS (severe acute respiratory syndrome) and the MERS (Middle East respiratory syndrome). This group of crown-shaped viruses can become deadly if it causes the patient to develop lower respiratory tract illnesses such as pneumonia or bronchitis. It is highly contagious in nature, spreading through the slightest form of saliva contact, whether it is coughing or kissing. The story of the Wuhan coronavirus sounds like history repeating itself after SARS shook up global markets in 2002-03.

It is worth recalling that pharma and biotech companies catering to the respiratory system and providing anti-viral medications were the ones that appreciated the most during the time of SARS, and the current situation does not appear very different. With a strong negative sentiment prevailing in most other sectors, pharma and biotech are perhaps the only sectors that could get a boost from a new bullish sentiment resulting from this virus. Based on the nature of the virus and the expected treatments, the following four stocks could benefit hugely given their presence in the field of anti-viral respiratory medication.

GlaxoSmithKline plc

Since the Wuhan coronavirus belongs to the same family as the SARS, it is important to recall those companies which benefitted the most from the SARS outbreak. While SARS may not have a defined cure even today, the most commonly prescribed form of treatment is the same as that for pneumonia. GlaxoSmithKline plc (NYSE:GSK) is one of the leaders in the space of anti-viral treatments for respiratory disorders like pneumonia.

The above chart shows how the company's stock grew as much as 35% during the SARS phase, which is quite significant for its size. It is worth highlighting that GlaxoSmithKline is a global player with its biggest markets being the U.S. and the UK. Respiratory oral health is one of its strongest segments, and it has a monopolistic position in many anti-viral medications. For example, its Shingrix vaccine for shingles is the only preventive vaccine for the disease across the globe. It has also performed strong research on HIV. The stock has appreciated by over 20% in the past twelve months and also provided a dividend yield of 4.32%, making it an excellent bet for investors.

Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is more of a play on the diagnostics aspect rather than the treatment aspect of the Wuhan virus. The company is one of the largest global biotech giants, and one of its most important offerings relevant to the Wuhan virus situation is its diagnostic capabilities. Abbott is known to provide rapid diagnostics systems for infectious diseases along with remote patient monitoring, informatics and automation solutions that are all very relevant to diagnose the Wuhan virus victims. It also has molecular point-of-care testing for HIV, influenza A and B and RSV.

Story continues

Abbott's relevance was so strong in the SARS era that it appreciated by over 30% in those times and is already up by around 22% in the past 12 months. Given the current situation, the upward momentum of the stock might continue for a while.

Gilead Sciences, Inc.

Biotech giant Gilead Sciences, Inc. (NASDAQ:GILD) was easily one of the biggest beneficiaries in the SARS outbreak, as it saw its stock appreciate more than 200% throughout the outbreak.

The reason for this appreciation is that Gilead gets most of its revenues from the anti-viral segment. The company's stock price has been stable throughout economic downturns and it is not without reason that the company has a 4.5-star business predictability rating on Gurufocus. Not only is it debt-free, it is known to distribute a good amount of dividend (current yield of 3.93%) to shareholders over and above capital appreciation. Not only has it done remarkable research on HIV, Gilead also has some very well known anti-viral brands in the market such as Atripla, Cayston, Sovaldi, Odefsey, Truvada, Biktarvy and so on. It is certainly going to be moving fast in the race to provide strong anti-viral treatments for the Wuhan coronavirus.

NanoViricides, Inc.

NanoViricides, Inc. (NNVC) is the only small, development-stage company on this list, but it is here for a reason. Since the news of the Wuhan virus outbreak, NanoViricides has seen its stock shoot up by as much as 349%.

The company, led by biotech veteran Dr. Anil Diwan, specializes in anti-viral research and had actively worked on MERS in the past. Its current research is also focused on treating viruses through its proprietary nanomedicine technology, where it uses anti-viral nanomachines known as "nanoviricides." The company has a decent pipeline of anti-viral drug candidates catering to diseases such as shingles, herpes, seasonal and potentially-epidemic influenzas, bird flu, HIV, cold sores, viral eye diseases and dengue viruses.

In fact, its most rapidly advancing drug candidate is a topical cream for the treatment of shingles, which is now advancing to the stage of IND application before progressing to human trials. While the company may not have significant revenues today, it hopes to start monetizing the progress of this cream through licensing agreements after the initial phases of the human trials. It has been one of the biggest beneficiaries of the Wuhan virus outbreak so far in terms of stock appreciation, and the upward momentum is expected to remain strong with the IND application results arriving soon.

Conclusion

The Wuhan coronavirus may have a huge negative impact on global markets over a span of time, but the pharma and biotech space is one where it presents a good opportunity. As its fears grip the world, companies like the ones mentioned above are working hard to capitalize on this opportunity and maximize their revenues. In such a situation, it is often beneficial for investors to be opportunistic and make the most returns through investing in these companies.

Disclosure: No positions.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.

Read this article:
These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus - Yahoo Finance

Nanomedicine: Ethical Issues and Societal Expectations
Speaker: PD Dr Johann S. Ach Academic Coordinator, Centre for Advanced Study in Bioethics, University of Mnster (D) CLINAM 7/ 2014, 7th Conference and Exhib...

By: TAUVOD

See the original post here:
Nanomedicine: Ethical Issues and Societal Expectations - Video

Nanomedicine Market 2019 report contains a focused socio-economic, political, and environmental analysis of the factors affecting the Nanomedicine industry. The report contains an analysis of the technologies involved in production, application and much more.

The report also carries in-depth case studies on the various countries which are actively involved in the Nanomedicine production. An analysis of the technical barriers, other issues, cost effectiveness affecting the Nanomedicine Market. Determining the opportunities, future of the Nanomedicine and its restraints becomes a lot easier with this report.

Request for Sample Copy of Nanomedicine Market Report athttps://www.pioneerreports.com/request-sample/46784

Details of Table of Content of Nanomedicine Market Report are as follows:

Chapter One Introduction of Nanomedicine Industry1.1 Brief Introduction of Nanomedicine1.2 Development of Nanomedicine Industry1.3 Status of Nanomedicine Industry

Chapter Two Manufacturing Technology of Nanomedicine2.1 Development of Nanomedicine Manufacturing Technology2.2 Analysis of Nanomedicine Manufacturing Technology2.3 Trends of Nanomedicine Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers3.1 Company A3.1.1 Company Profile3.1.2 Product Information3.1.3 2014-2019 Production Information3.1.4 Contact Information3.2 Company B3.2.1 Company Profile3.2.2 Product Information3.2.3 2014-2019 Production Information3.2.4 Contact Information3.3 Company C3.2.1 Company Profile3.3.2 Product Information3.3.3 2014-2019 Production Information3.3.4 Contact Information3.4 Company D3.4.1 Company Profile3.4.2 Product Information3.4.3 2014-2019 Production Information3.4.4 Contact Information&

Look into Table of Content of Nanomedicine Market Report at https://www.pioneerreports.com/TOC/46784

Regions Covered in Nanomedicine Market are:-

Chapter Four 2014-2019 Global and Southeast Asia Market of Nanomedicine4.1 2014-2019 Global Capacity, Production and Production Value of Nanomedicine Industry4.2 2014-2019 Global Cost and Profit of Nanomedicine Industry4.3 Market Comparison of Global and Southeast Asia Nanomedicine Industry4.4 2014-2019 Global and Southeast Asia Supply and Consumption of Nanomedicine4.5 2014-2019 Southeast Asia Import and Export of Nanomedicine

Chapter Five Market Status of Nanomedicine Industry5.1 Market Competition of Nanomedicine Industry by Company5.2 Market Competition of Nanomedicine Industry by Country (USA, EU, Japan, Southeast Asia etc.)5.3 Market Analysis of Nanomedicine Consumption by Application/Type

Chapter Six 2019-2024 Market Forecast of Global and Southeast Asia Nanomedicine Industry6.1 2019-2024 Global and Southeast Asia Capacity, Production, and Production Value of Nanomedicine6.2 2019-2024 Nanomedicine Industry Cost and Profit Estimation6.3 2019-2024 Global and Southeast Asia Market Share of Nanomedicine6.4 2019-2024 Global and Southeast Asia Supply and Consumption of Nanomedicine6.5 2019-2024 Southeast Asia Import and Export of Nanomedicine

Chapter Seven Analysis of Nanomedicine Industry Chain7.1 Industry Chain Structure7.2 Upstream Raw Materials7.3 Downstream Industry

Chapter Eight Global and Southeast Asia Economic Impact on Nanomedicine Industry8.1 Global and Southeast Asia Macroeconomic Environment Analysis8.1.1 Global Macroeconomic Analysis8.1.2 Southeast Asia Macroeconomic Analysis8.2 Global and Southeast Asia Macroeconomic Environment Development Trend8.2.1 Global Macroeconomic Outlook8.2.2 Southeast Asia Macroeconomic Outlook8.3 Effects to Nanomedicine Industry

Chapter Nine Market Dynamics of Nanomedicine Industry9.1 Nanomedicine Industry News9.2 Nanomedicine Industry Development Challenges9.3 Nanomedicine Industry Development Opportunities

Chapter Ten Proposals for New Project10.1 Market Entry Strategies10.2 Countermeasures of Economic Impact10.3 Marketing Channels10.4 Feasibility Studies of New Project Investment

Chapter Eleven Research Conclusions of Global and Southeast Asia Nanomedicine Industry

Key market insights include:

1. The analysis of Nanomedicine market provides market size and growth rate for the forecast period 2019-2024.

2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the Nanomedicine market.

3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.

4. It offers a complete overview of market segments and the regional outlook of Nanomedicine market.

5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

In this study, the years considered to estimate the market size of Nanomedicine Market are as follows:-

Single User Licence Price: USD 3900

No Of Pages in Nanomedicine Market Report: 136

Purchase of Nanomedicine Market Report at:https://www.pioneerreports.com/checkout/46784

Continued here:
Nanomedicine Market Analysis Global Opportunities, Revenue, Demand and Geographical Forecast To 2024 - The Connection

Qualtrics increased its initial public offering range to $27 to $29 per share Monday, positioning the company to be the largest IPO to come from Utah.

Subscribe to the Crunchbase Daily

At that heightened price range, the company could be valued at up to $15 billion and raise about $1.5 billion through its IPO. Qualtrics, which provides software to help gauge employee, product, and customer experience and competes with companies like SurveyMonkey, previously set an IPO range of between $20 and $24 before raising it to between $22 and $26.

Qualtrics will be one of 67 public companies based in Utah, according to Crunchbase data. If it prices at the top of its range, it would raise nearly twice the amount of Utahs current largest IPO, EnergySolutions November 2007 initial public offering, which raised about $690 million.

Utahs burgeoning startup and tech scene isnt entirely new. The Provo-Lehi-Salt Lake City area is known as Silicon Slopes, and has created a tech community of its own. Venture-backed companies based in the state raised $1.2 billion in funding last year, per preliminary Crunchbase data.

But Qualtrics IPO is a big deal for the state, as was its previous exit when it was acquired by SAP. It could also lead to a flywheel effect for more big exits coming out of the state, according to Joe Kaiser, director of Utah-based Mercato Partners, a growth equity firm that invests in technology and consumer businesses.

Qualtrics has this cluster of incredibly talented people who were not here before it, but now are rooted in the Utah market, said Kaiser, a Utah transplant who moved to the state for business. He helped take Lehi, Utah-based Vivint Solar public in 2014 and ended up staying.

Now, when Qualtrics alums want to start the next cohort of great companies or the next generation of entrepreneurs is looking for leaders to help build their startups, theyll be able to tap a pool of talent created by companies like Qualtrics and Domo.

It has now incubated the local market with exceptional talent that now knows how to work in a hypergrowth environment that lacks structure initially, Kaiser said.

Qualtrics was on the verge of an IPO in November 2018 when enterprise software maker SAP announced plans to buy it for $8 billion. At the time, Qualtrics was SAPs second-largest acquisition ever, only behind the $8.3 billion acquisition of travel and expense management platform Concur, according to CNBC. The acquisition was also Utahs largest of the year.

SAP announced in July 2020 that it instead intended to take Qualtrics public after all, and the enterprise software-maker filed formally for an IPO for Qualtrics in December.

We decided that an IPO would provide the greatest opportunity for Qualtrics to grow the experience management category, serve its customers, explore its own acquisition strategy and continue building the best talent, SAP CEO Christian Klein said in a July statement. SAP will remain Qualtrics largest and most important go-to-market and research and development (R&D) partner while giving Qualtrics greater independence to broaden its base by partnering and building out the entire experience management ecosystem.

Qualtrics acquisition was one of two $1 billion-plus acquisitions to come from the state in 2019, with HealthEquity buying employee benefits manager WageWorks for $2.12 billion. It was also the largest acquisition of a Utah-based company ever, according to Crunchbase data. The $8 billion acquisition by SAP was around four times larger than the second-largest acquisition of a Utah company, when Blackstone bought Vivint Smart Home for $2 billion in September 2012.

As Kaiser put it, Utah companies are going for Silicon Valley prices, and he only expects transaction volume to climb. Mercato Partners portfolio companies have had five exits since March 2020, with three of those being over the $1 billion mark.

SoFi announced plans to acquire Salt Lake City-based Galileo Financial Technologies in April for $1.2 billion. Thoma Bravo acquired Venafi for $1.15 billion last year, and Ericsson bought Cradlepoint for $1.1 billion. Other notable recent acquisitions of Utah companies are VMWare buying SaltStack and Rubicon Technology Partners buying Central Logic.

Its not like one Utah company is buying another Utah company, this is much much broader than that, Kaiser said.

Qualtrics also marks the second notable public exit for a Utah-based company in recent months. Clene Nanomedicine, a biopharmaceutical company based in Salt Lake City, went public around three weeks after merging with a special purpose acquisition company.

To John Yoon, Mercato Partners vice president of marketing practice, tech companies being more flexible with remote work will only help Utahs burgeoning tech scene and the next generation of tech companies.

It starts with big companies encouraging people to move, or allowing people to move and once they move here, they dont have to stay with the big company. And thats where weve started to step in as investors, Yoon said, referring to the phenomenon as the pollination effect.

Startups in Utah will also benefit from the regional hubs that some large tech companies are starting to accommodate remote work, Kaiser said. Once talent moves to a place like Utah, Columbus or Minneapolis and settles down there, they could be more inclined to join a local startup.

Theyve set down roots, theyve seen how much easier life can be and they couple it with Now theres a cool startup in town and they need a backend engineer and this is what I do, Kaiser said.

Illustration: Li-Anne Dias

Editors Note: This story was updated Monday to reflect Qualtrics increased IPO price range.

Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.

Read this article:
Qualtrics IPO, Poised To Be Utah's Largest, Is Validation Of State's Burgeoning Tech Scene - Crunchbase News

CSIR-Centre for Cellular & Molecular Biology (CCMB) scientists in collaboration with CSIR-National Chemical Laboratory (NCL) announced on Thursday that they have made progress towards developing a non-toxic bio-drug derived from turmeric through a gene silencing approach to treat cancer.

RNA interference (RNAi) is a gene silencing approach and a promising tool for targeted and focused therapy for chronic diseases like cancer. The lack of safe and effective delivery methods for RNAi molecules is one of the key challenges against using RNAi-based therapy in biological systems.

CCMBs Dr. Lekha Dinesh Kumar and her group in collaboration with NCLs polymer science and engineering division have developed nano-curcumin structures (derived from turmeric) to encapsulate the RNAi and other molecules that aid in targeting specific tissues.

The proposed bio-drug is bio-compatible with a higher uptake efficiency, and shows effective site-specific delivery with regression of tumors in two different mouse models of colon and breast cancer. The use of curcumin, a well-known nutraceutical with high anti-cancer and anti-inflammatory properties with RNAi, showed tumor retardation with six months survival in aggressive models of colon and breast cancer, says Dr. Kumar.

Cancer is one of the leading causes of death worldwide and the quest to find plausible therapeutic interventions to replace non-specific chemo drugs has been leading to the development of novel strategies to combat cancer. This work has been published in the journal Nanoscale.

In another study with the School of Nanosciences, Central University, Gujarat and Centre for Advanced Materials and Industrial Chemistry, RMIT Australia, they designed an eco-friendly and pH-responsive dietary fibre inulin-based nanodevice to target colon cancer.

This device suggests the possibility of substituting synthetic substances with natural compounds in bio-drug formulations for better bio-degradability, tissue accumulation, and lesser toxicity.

The results from this work have been published in the journal Nanomedicine, said an official release.

We have demonstrated that RNAi combined with appropriate targeting agents and encapsulations made of natural biomaterials have high translational capacity in mice models of cancer. This group of bio-drugs can revolutionize cancer therapeutics. But, it should be assessed in other cancer model systems to bring out the utility of these therapeutics in the clinical trials, she added.

Read this article:
Now, a bio-drug derived from turmeric to treat cancer - The Hindu

Oct. 13, 2020 06:00 UTC

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the first patient has been injected in its phase I study evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer. The trial is a being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.

Two additional trials from the clinical collaboration received safe to proceed notifications from the United States Food and Drug Administration (FDA): (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation; and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. All current and future trials in this clinical collaboration are sponsored and executed by MD Anderson.

A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with Pancreatic Cancer

Pancreatic cancer is a rare, deadly disease that accounts for approximately 3% of all cancers and has a 5-year survival rate of 9%1.

This pancreatic cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D) of NBTXR3 activated by radiation therapy; and (ii) expansion at RP2D.

The patient population will include adults (age 18 years) with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. Up to 24 subjects will be enrolled and the planned enrollment period is 18 months.

The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.

Two Additional Phase I Studies in Lung and Esophageal Cancer Pending

A phase I trial investigating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation, and a phase I trial investigating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer have been deemed safe to proceed by FDA. Safe to proceed notifications are delivered once the agency is satisfied with the information contained in an investigational new drug application (IND) or any additional information or clarification has been provided.

Lung cancer is the second most common cancer type, and the leading cause of cancer death for both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5-year survival rate of 24% worldwide.2

The lung cancer trial is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with inoperable, locoregional recurrent (LRR) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (IMRT) monotherapy in 10 patients. Up to 24 subjects will be enrolled in cohort 2. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 36 months.

Esophageal cancer is the eighth most common cancer type and the sixth most common cause of cancer deaths worldwide. The 5-year survival rate in the US is 20%, and 10% in Europe3.

The esophageal cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiation therapy with concurrent chemotherapy, as per standard of care; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment nave and radiographically non-metastatic at screening. Up to 24 subjects will be enrolled. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 24 months.

Next Steps for Clinical Collaboration with MD Anderson

The clinical collaboration between Nanobiotix and MD Anderson includes plans for additional clinical trials across several indications. Beyond the three (3) trials mentioned above, the other trials, including four (4) combination trials with immune checkpoint inhibitors and NBTXR3 activated by radiation therapy, are in preparation and will launch in due time.

***

About NBTXR3

NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

1 https://www.cancer.net/cancer-types/pancreatic-cancer/statistics

2 https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics

3 https://www.cancer.net/cancer-types/esophageal-cancer/statistics

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005825/en/

Read the original:
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From US FDA -...